title: Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model.
abstract: Camptothecin (CPT) exhibits very strong antitumor effects by inhibiting the activity of DNA topoisomerase I, but its application is greatly limited due to its low solubility and the instability of the active lactone form. To overcome these shortcomings, in the present study, we prepared novel camptothecin nanocolloids based on N,N,N-trimethyl chitosan (CPT-TMC) to efficiently and safely administer CPT systemically. Herein, we investigated the antitumor activity of CPT-TMC against a murine Balb/c myeloma model. Our results showed that CPT-TMC more effectively inhibited tumor growth and prolonged survival time than CPT in vivo, but no statistical difference was observed in vitro between CPT-TMC and CPT. These findings suggest that N,N,N-trimethyl chitosan could increase the stability and the antitumor effect of CPT and CPT-TMC is a potential approach for the effective treatment of multiple myeloma.
authors.affiliation: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, PR China.
authors.forename: Zhengguang
authors.initials: Z
authors.lastname: Li
authors.forename: Xingyi
authors.initials: X
authors.lastname: Li
authors.forename: Zhixing
authors.initials: Z
authors.lastname: Cao
authors.forename: Youzhi
authors.initials: Y
authors.lastname: Xu
authors.forename: Hongjun
authors.initials: H
authors.lastname: Lin
authors.forename: Yinglan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Yuquan
authors.initials: Y
authors.lastname: Wei
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Qian
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000737:chemistry; D017209:Apoptosis / Q000187:drug effects; D002166:Camptothecin / Q000008:administration & dosage* / Q000737:chemistry; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D048271:Chitosan / Q000737:chemistry*; D003102:Colloids; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D004339:Drug Compounding; D004355:Drug Stability; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D053758:Nanoparticles; D012995:Solubility; D013997:Time Factors; D059004:Topoisomerase I Inhibitors / Q000008:administration & dosage* / Q000737:chemistry; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D003102:Colloids; D004337:Drug Carriers; C118071:N-trimethyl chitosan chloride; D059004:Topoisomerase I Inhibitors; D048271:Chitosan; D002166:Camptothecin